Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

Denali has two wholly-owned, late-stage development programs — DNL310 for (Hunter syndrome) and DNL343 (eIF2B activator) — for amyotrophic lateral sclerosis (ALS). DNL310, or tividenofusp alfa, is an ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years ...

Imagine a world where you can control devices freely, simply by thinking about what you want to do. A new collaboration between the East China University of Science and Technology (ECUST) and Chinese ...

This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...

Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...

The University of Ghana (UG), in collaboration with Google Research Africa and the University College of London’s (UCL) ...

Neurosense Therapeutics (NASDAQ:NRSN) is developing novel treatments for neurodegenerative diseases like amyotrophic lateral ...

Founded in 2011 under the name M3 Biotechnology, Athira has been trying to develop small molecule drugs that help regenerate ...

BUENOS AIRES — Three people were charged in connection with the death of Liam Payne, a former member of musical group One ...